Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.

Education

Biotechnology

Escalier Biosciences

Raju Mohan

Chris Krueger

John Nuss

The Leadership Team at Escalier Biosciences is responsible for setting the overall strategic direction and vision of the company, guiding the development of innovative RORγt inverse agonists for psoriasis treatment. This team, composed of founding members and key executives, collaborates to align scientific research with business goals, ensuring effective resource allocation, regulatory compliance, and market entry strategies for both topical and oral therapeutic solutions.

Leadership Team

About

Team members

Other teams at Escalier Biosciences

Advisory Board